{"id":508804,"date":"2020-09-28T13:58:01","date_gmt":"2020-09-28T13:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=508804"},"modified":"2020-09-28T13:58:01","modified_gmt":"2020-09-28T13:58:01","slug":"meningioma-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/meningioma-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_508804.html","title":{"rendered":"Meningioma Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Meningioma Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Meningioma Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Meningioma Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(Albany, US) DelveInsight has launched a new report on<strong> &#8220;Meningioma Market Insights, Epidemiology, and Market Forecast-2030&#8221;.<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s<strong> &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/meningioma-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">Meningioma Market Insights, Epidemiology, and Market Forecast-2030<\/a>&#8221; <\/strong>report delivers an in-depth understanding of the Meningioma , historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the facts:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per DelveInsight, Increasing trend could be artefactual and could be the result of an aging population, improvement in health access and diagnostic procedures, changes in coding classification for tumors recorded in registries, and\/or an increase in the rate of histological confirmation, even in the elderly.<\/li>\n<li>Even if comparisons are made difficult due to differences in methodologies, available annual incidence rates (sex- and age-standardized, generally on the US or World standard population), provided by population-based registries range from 1.3\/100,000 to 7.8\/100,000 for cerebral meningiomas.<\/li>\n<li>Atypical and malignant meningiomas comprise a small fraction of the total (~5%) and have a slight male predominance. Reported rates for Black Non-Hispanics are slightly higher (6.67) than for White Non-Hispanic and Hispanics (5.90 and 5.94, respectively).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/meningioma-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/meningioma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Meningioma , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Meningioma epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Meningioma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Meningioma market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Meningioma market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/meningioma-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\"><strong>Meningiomas<\/strong><\/a> are the most common benign intracranial tumor. They originate from arachnoid cap cells, which are cells within the thin, spiderweb-like membrane that covers the brain and spinal cord. The arachnoid is one of three protective layers, collectively known as the meninges, which surround the brain and the spinal cord. The other two layers of the meninges are the dura mater and pia mater. Although the majority of meningiomas are benign, these tumors can grow slowly until they are very large, if left undiscovered, and, in some locations, can be severely disabling and life-threatening. Other forms of meningioma may be more aggressive. Most patients develop a single meningioma; however, some patients may develop several tumors growing simultaneously in other locations of the brain or spinal cord.<\/p>\n<p style=\"text-align: justify;\">Often, meningiomas cause no symptoms and require no immediate treatment. But the growth of benign meningiomas can cause serious problems. In some cases, such growth can be fatal. Some meningiomas are classified as atypical. These are not considered either benign or malignant (cancerous). But they may become malignant. A small number of meningiomas are cancerous. They tend to grow quickly. They also can spread to other parts of the brain and beyond, often to the lungs.<\/p>\n<p style=\"text-align: justify;\"><em><strong>Risk factors for a meningioma include radiation treatment, female hormones, an inherited nervous system disorder, or obesity.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">The WHO classification of brain tumors is the most widely utilized tool in grading tumor types. The WHO classification scheme recognizes 15 variations of meningiomas according to their cell type as seen under a microscope. These variations are called meningioma subtypes &ndash; the technical term for these cell variations is histological subtypes. These histological subtypes are organized into three grades that generally reflects the rate of growth and the likelihood of recurrence based on cytological features.<\/p>\n<p style=\"text-align: justify;\">Atypical meningiomas (WHO grade II, which account for 18% of meningioma cases) exhibit increased tissue and cell abnormalities. These tumors grow at a faster rate than benign meningiomas and are often characterized by brain invasion. Atypical meningiomas have a higher likelihood of recurrence than benign meningiomas (WHO grade I).<\/p>\n<p style=\"text-align: justify;\">Malignant meningiomas (WHO grade III) show increased cellular abnormalities and grow at a faster rate than benign and atypical meningiomas. Malignant meningiomas are the most likely to invade the brain and recur more frequently than the other two subtypes.<\/p>\n<p style=\"text-align: justify;\">It can be difficult to diagnose meningiomas for several reasons. Because the majority of meningiomas are slow-growing tumors and primarily affect adults, symptoms may be so subtle that the patient and\/or doctor may attribute them to the normal signs of aging. Adding to the confusion is that some of the symptoms associated with meningiomas can also be due to other medical conditions. Misdiagnosis is not uncommon and, may take several years for correct diagnosis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/meningioma-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/meningioma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Ariad Pharmaceutics<\/li>\n<li>Clarity Pharmaceuticals<\/li>\n<li>Actuate Therapeutics<\/li>\n<li>Abbvie<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Drugs covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Brigatinib<\/li>\n<li>SARTATE<\/li>\n<li>9-ING-41<\/li>\n<li>Veliparib<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/meningioma-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/meningioma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of Meningioma<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. Competitive Intelligence Analysis for Meningioma<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4. Meningioma : Market Overview at a Glance<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. Meningioma Total Market Share (%) Distribution in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2. Meningioma Total Market Share (%) Distribution in 2030<\/p>\n<p style=\"text-align: justify;\"><strong>5. Meningioma : Disease Background and Overview<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2. Sign and Symptoms&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.3. Pathophysiology&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.4. Risk Factors&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.5. Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>6. Patient Journey<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Meningioma Epidemiology and Patient Population<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.1. Meningioma Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.4. United States Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.1. Meningioma Epidemiology Scenario in the United States (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.5. EU-5 Country-wise Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.1. Germany Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.1.1. Meningioma Epidemiology Scenario in Germany (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.2. France Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.2.1. Meningioma Epidemiology Scenario in France (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.3. Italy Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.3.1. Meningioma Epidemiology Scenario in Italy (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.4. Spain Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.4.1. Meningioma Epidemiology Scenario in Spain (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.5. United Kingdom Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.5.1. Meningioma Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.6. Japan Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.6.1. Meningioma Epidemiology Scenario in Japan (2017-2030)<\/p>\n<p style=\"text-align: justify;\"><strong>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1. Meningioma Treatment and Management<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2. Meningioma Treatment Algorithm&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>9. Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Key Endpoints of Meningioma Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Marketed Products<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.1. List of Marketed Products in the 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.5. Summary of Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><strong>12. Emerging Therapies<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.5. Product Profile<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><strong>13. Meningioma : Seven Major Market Analysis<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.2. Meningioma Market Size in 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.3. Meningioma Market Size by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\"><strong>14. Attribute analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. 7MM: Market Outlook<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1. United States: Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.1. Meningioma Total Market Size in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.2. Meningioma Market Size by Therapies in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2. EU-5 countries: Market Size and Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.3. Germany Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.1. Meningioma Total Market Size in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.2. Meningioma Market Size by Therapies in Germany<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.4. France Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.1. Meningioma Total Market Size in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.2. Meningioma Market Size by Therapies in France<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.5. Italy Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.1. Meningioma Total Market Size in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.2. Meningioma Market Size by Therapies in Italy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.6. Spain Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.1. Meningioma Total Market Size in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.2. Meningioma Market Size by Therapies in Spain<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.7. United Kingdom Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.1. Meningioma Total Market Size in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.2. Meningioma Market Size by Therapies in the United Kingdom<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.8. Japan Market Outlook<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.1. Japan Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.2. Meningioma Total Market Size in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.3. Meningioma Market Size by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\"><strong>16. Access and Reimbursement Overview of Meningioma<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>17. KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Market Drivers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Market Barriers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>21. DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>22. Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>23. About DelveInsight<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=meningioma-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/meningioma-market?utm_source=Pressrelease&#038;utm_medium=Pressrelease&#038;utm_campaign=Pressrelease\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/meningioma-market?utm_source=Pressrelease&#038;utm_medium=Pressrelease&#038;utm_campaign=Pressrelease<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/meningioma-market?utm_source=Pressrelease&#038;utm_medium=Pressrelease&#038;utm_campaign=Pressrelease\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=meningioma-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Meningioma Market Insights, Epidemiology, and Market Forecast-2030&#8221; (Albany, US) DelveInsight has launched a new report on &#8220;Meningioma Market Insights, Epidemiology, and Market Forecast-2030&#8221;. &nbsp; DelveInsight&#8217;s &#8220;Meningioma Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Meningioma &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/meningioma-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_508804.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-508804","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=508804"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508804\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=508804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=508804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=508804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}